Navigation Links
Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol
Date:2/6/2009

SCOTTSDALE, Ariz., Feb. 6 /PRNewswire/ -- Cancer Clinics of Excellence, LLC, the nation's only physician-driven network of community oncologists, announced the completion of its 62nd comprehensive Evidence-Based Treatment Protocol covering 11 of the leading oncology disease states at the 4th Annual Community Oncology Conference today. "Our 200+ member national oncology group is now fully prepared to launch the protocols across its network in 16 States," announced Frederick M. Schnell, MD, Central Georgia Cancer Care, Macon, GA, and CCE's Chief Clinical Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080612/AQTH094LOGO)

"CCE's proprietary Evidence-based Treatment Protocols represent a significant advantage for community oncology practices around the country as they assimilate a vast amount of information into a usable clinical outcome tool. By integrating the protocols into the member oncology practices, physicians will be able to demonstrate to consumers the value of practicing evidence-based medicine across the entire continuum of care in oncology," stated Dr. Schnell. "The sheer breadth of these protocols is testament to the diligence of our 11 national physician User Groups and the cohesiveness of the network. With the release of our 62nd protocol, our broad network of community oncologists utilizes empirical, evidence-based and referenced protocols in treating our patients. This assures that we remain focused on value based medicine while using the most current evidence to treat our patients," added Arthur "Chip" Staddon, MD, Pennsylvania Oncology, Philadelphia, PA, Chairman of CCE.

"CCE provides its growing membership of physicians with a robust set of tools and resources including an integrated information technology platform, proprietary Evidence-based Treatment Protocols, and a collaborative model of care planning and management that are necessary to demonstrate clinical efficiency and outcomes," stated J. Ike Nicoll, CEO of CCE. "Given the current challenges in the healthcare market, CCE's approach will have a meaningful effect on improved clinical quality and economic outcome as our member practices collectively treat over 150,000 cancer patients annually. Therefore our commitment to evidence-based medicine is consistent with the country's need to raise the standards of quality while keeping healthcare affordable," added Mr. Nicoll.

The Co-Chairs of the 4th Annual Community Oncology Conference, CCE's Chief Medical Officer, Linda Bosserman, MD, of Wilshire Oncology Medical Group in Southern California and David Henry, MD, of Pennsylvania Oncology, in Philadelphia opened the meeting. Also speaking were CCE members, Patrick Cobb, MD, Hematology Oncology Centers of the Northern Rockies, Billings, MT and President of the Community Oncology Alliance, and Kent Butcher, CEO of Oklahoma Oncology, Tulsa, OK.

About Cancer Clinics of Excellence, LLC

Cancer Clinics of Excellence is the nations only practice-owned and physician driven network that empowers oncologists to deliver proven, evidence-based treatment in community settings while ensuring the performance of their practices. For more information, visit us at www.cce.us.com.


'/>"/>
SOURCE Cancer Clinics of Excellence, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a ... biotechnology industries to improve patient outcomes and quality of life, will now be ... are being attributed to new regulatory requirements for all new drug products, including ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):